Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early ‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up

ConclusionsFor premenopausal HR+ breast cancer patients, HER2 positivity alone is an indication for the addition of OFS in adjuvant endocrine therapy. Age, histological grade, lymph node status, the expression of PR, and OFS treatment were independent prognostic factors in this population.

Source: Thoracic Cancer - January 8, 2024 Category: Cancer & Oncology Authors: Jie Ju, Song ‐Lin Gao, Jia‐Yu Wang, Die Sang, Yi‐Kun Kang, Xue Wang, Jian Yue, You Shuai, Yi‐Xin Qi, Peng Yuan Tags: ORIGINAL ARTICLE Source Type: research